Status:
UNKNOWN
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Lead Sponsor:
Turkish Society of Cardiology
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
18+ years
Brief Summary
Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis
Eligibility Criteria
Inclusion
- Patients with left ventricular hypertrophy without left ventricular pressure or volume (IVS≥13mm)
- Patients with left ventricular hypertrophy and hypertension or aortic stenosis without left ventricular pressure or volume (IVS\>15mm)
Exclusion
- Patients with left ventricular pressure or volume except the ones with aortic stenosis and arterial hypertension
- Patients with sigmoid septum and their hypertrophy limited in sigmoid area
- Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV morhpology and genetic testing
Key Trial Info
Start Date :
September 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2087 Patients enrolled
Trial Details
Trial ID
NCT04915235
Start Date
September 18 2020
End Date
December 31 2025
Last Update
June 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dokuz Eylul University Faculty of Medicine
Izmir, Turkey (Türkiye)